SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.
Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.
-- This week at the 39th Annual Meeting on Women's Cancer hosted by the
Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented
positive interim results from the company's ongoing Phase 2 clinical trial
of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant
ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent
SNS-595 at a dose of 48 mg/m2 administered once every three weeks,
with the majority of these women having been enrolled since October.
Forty-five women have sufficient follow up to yield useful safety
results and 35 are evaluable for best response using GOG-RECIST
-- In this trial, SNS-595 has demonstrated disease control (defined as
stable disease, partial response or complete response), with 31 of
35 of evaluable patients having best responses of stable disease or
|SOURCE Sunesis Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved